2 results
Approved WMOCompleted
The objective of this open label phase IIa trial is to evaluate the efficacy and tolerability of a once a week dose of 200 mg R126638, for a maximum of 12 weeks, for the treatment of toenail onychomycosis.
Approved WMOCompleted
The primary objective is to evaluate the effect of UDCA and ezetimibe on cholesterol elimination assessed as total faecal sterol concentration. Secondary objective is to assess the effect of UDCA and ezetimibe on plasma lipid profile/composition.